Hypertension in Diabetic Nephropathy: Epidemiology, Mechanisms, and Management

Overview

Journal Adv Chronic Kidney Dis

Specialty Nephrology

Date 2011 Jan 13

PMID 21224028

Citations 84

Authors

Peter N Van Buren

Robert Toto

Affiliations

Soon will be listed here.

Abstract

Hypertension is highly prevalent in patients with diabetic nephropathy. Diabetic nephropathy is the leading cause of CKD and end-stage kidney disease in the United States. The etiology of hypertension in diabetic nephropathy involves mechanisms with multiple inter-related mediators that result in renal sodium reabsorption and peripheral vasoconstriction. The management of hypertension in these patients is focused on treatments that target these mediators. Clinical trials have established that drugs that inhibit the renin-angiotensin-aldosterone system should be used as first-line agents on the basis of their ability to slow down progression of kidney disease and lower albuminuria. There is further interest into how the combination of drugs that inhibit this pathway at multiple steps will contribute further to the management of hypertension and diabetic nephropathy. This article presents an updated review of the mechanisms involved in hypertension in patients with diabetic nephropathy. It also reviews the past clinical trials using single agents as therapeutics and the more recent trials involving novel drugs or drug combinations used to treat these patients. Retrospective analyses of multiple studies are included to better examine the significance of the currently proposed blood pressure targets for patients with diabetic nephropathy.

Citing Articles

Time in target range of systolic blood pressure and eGFR slope in patients with type 2 diabetes.

Cheng Y, Zhu X, Xu Y, Zou J, Huang W, Tian J Hypertens Res. 2025; .

PMID: 40065086 DOI: 10.1038/s41440-025-02173-4.

The role of advanced glycation end products between thyroid function and diabetic nephropathy and metabolic disorders.

Zhang Y, Wang Y, Kang Q, Chen Y, Ai L, Hu K Sci Rep. 2025; 15(1):7202.

PMID: 40021692 PMC: 11871035. DOI: 10.1038/s41598-025-88806-7.

Diabetic Nephropathy-Associated Impaired Aortic Function Is Not Mediated by Mean Arterial Pressure and Its Determinants.

Hsu H, Mazibuko M, Robinson C, Dlongolo N, Woodiwiss A, Teckie G J Clin Med. 2025; 13(24.

PMID: 39768750 PMC: 11727795. DOI: 10.3390/jcm13247827.

Self-care practices among hypertensive patients at the primary health care centers in Unaizah city, Saudi Arabia.

Siam B, Aldakeel H, Alrasheeday A, Alsaqri S, Alshammari B, Alshammari F Front Med (Lausanne). 2024; 11:1290670.

PMID: 39697200 PMC: 11652135. DOI: 10.3389/fmed.2024.1290670.

Social Determinants of Health for Cardiovascular-Kidney-Metabolic Syndrome Among Patients With Diabetes.

Belay K, Feleke Y, Alemneh T, Haile A, Abebe D J Endocr Soc. 2024; 9(1):bvae208.

PMID: 39669651 PMC: 11635457. DOI: 10.1210/jendso/bvae208.

References

Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R . Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol. 2003; 23(8):1455-9. DOI: 10.1161/01.ATV.0000081742.92006.59. View

Konoshita T, Wakahara S, Mizuno S, Motomura M, Aoyama C, Makino Y . Tissue gene expression of renin-angiotensin system in human type 2 diabetic nephropathy. Diabetes Care. 2006; 29(4):848-52. DOI: 10.2337/diacare.29.04.06.dc05-1873. View

Schjoedt K, Andersen S, Rossing P, Tarnow L, Parving H . Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia. 2004; 47(11):1936-9. DOI: 10.1007/s00125-004-1542-0. View

Bakris G, Weir M, Shanifar S, Zhang Z, Douglas J, van Dijk D . Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med. 2003; 163(13):1555-65. DOI: 10.1001/archinte.163.13.1555. View

Muniyappa R, Quon M . Insulin action and insulin resistance in vascular endothelium. Curr Opin Clin Nutr Metab Care. 2007; 10(4):523-30. DOI: 10.1097/MCO.0b013e32819f8ecd. View

Lewis E, Hunsicker L, Bain R, Rohde R . The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993; 329(20):1456-62. DOI: 10.1056/NEJM199311113292004. View

Jacobsen P, Andersen S, Rossing K, Jensen B, Parving H . Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int. 2003; 63(5):1874-80. DOI: 10.1046/j.1523-1755.2003.00940.x. View

Fitzgerald S, Brands M . Nitric oxide may be required to prevent hypertension at the onset of diabetes. Am J Physiol Endocrinol Metab. 2000; 279(4):E762-8. DOI: 10.1152/ajpendo.2000.279.4.E762. View

Parving H, Gall M, Skott P, Jorgensen H, Lokkegaard H, Jorgensen F . Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int. 1992; 41(4):758-62. DOI: 10.1038/ki.1992.118. View

10.

Parving H, Hommel E, Jensen B, Hansen H . Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int. 2001; 60(1):228-34. DOI: 10.1046/j.1523-1755.2001.00790.x. View

11.

Tuck M, Corry D, Trujillo A . Salt-sensitive blood pressure and exaggerated vascular reactivity in the hypertension of diabetes mellitus. Am J Med. 1990; 88(3):210-6. DOI: 10.1016/0002-9343(90)90144-3. View

12.

Brands M, Labazi H . Role of glomerular filtration rate in controlling blood pressure early in diabetes. Hypertension. 2008; 52(2):188-94. PMC: 2692107. DOI: 10.1161/HYPERTENSIONAHA.107.090647. View

13.

Dhaun N, Ferro C, Davenport A, Haynes W, Goddard J, Webb D . Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. Nephrol Dial Transplant. 2007; 22(11):3228-34. DOI: 10.1093/ndt/gfm364. View

14.

Koyama H, Tabata T, Nishzawa Y, Inoue T, Morii H, Yamaji T . Plasma endothelin levels in patients with uraemia. Lancet. 1989; 1(8645):991-2. DOI: 10.1016/s0140-6736(89)92631-7. View

15.

Persson F, Rossing P, Schjoedt K, Juhl T, Tarnow L, Stehouwer C . Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int. 2008; 73(12):1419-25. DOI: 10.1038/ki.2008.68. View

16.

DeFronzo R . The effect of insulin on renal sodium metabolism. A review with clinical implications. Diabetologia. 1981; 21(3):165-71. DOI: 10.1007/BF00252649. View

17.

Abbasi F, Asagmi T, Cooke J, Lamendola C, McLaughlin T, Reaven G . Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol. 2001; 88(10):1201-3. DOI: 10.1016/s0002-9149(01)02063-x. View

18.

Prabhakar S . Role of nitric oxide in diabetic nephropathy. Semin Nephrol. 2004; 24(4):333-44. DOI: 10.1016/j.semnephrol.2004.04.005. View

19.

Ismail N, Becker B, Strzelczyk P, Ritz E . Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int. 1999; 55(1):1-28. DOI: 10.1046/j.1523-1755.1999.00232.x. View

20.

Cushman W, Evans G, Byington R, Goff Jr D, Grimm Jr R, Cutler J . Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17):1575-85. PMC: 4123215. DOI: 10.1056/NEJMoa1001286. View